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In Saccharomyces cerevisiae 6 closely related proteins (Did2p, Vps2p, Vps24p, Vps32p, Vps60p, Vps20p) form part of the extended ESCRT
III complex. This complex is required for the formation of multivesicular bodies and the degradation of internalized transmembrane receptor
proteins. In contrast the human genome encodes 10 homologous proteins (CHMP1A (approved gene symbol PCOLN3), 1B, 2A, 2B, 3 (approved
gene symbol VPS24), 4A, 4B, 4C, 5, and 6). In this study we have performed a series of protein interaction experiments to generate a more
comprehensive picture of the human CHMP protein-interaction network. Our results describe novel interactions between known components of
the human ESCRT III complex and identify a range of putative binding partners, which may indicate new ways in which the function of human
CHMP proteins may be regulated. In particular, we show that two further MIT domain-containing proteins (AMSH/STAMBP and LOC129531)
interact with multiple components of the human ESCRT III complex.
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receptors can be regulated through a process of selective
internalization and degradation. In some cases receptor
internalization is initiated by the addition of a cytoplasmic
mono-ubiquitin tag [1–3]. Ubiquitinated receptors are first
endocytosed into clathrin-coated vesicles, which fuse with
tubular-sorting endosomes. In this compartment receptors are
either recycled back to the plasma membrane or segregated
into membrane domains, which bud internally to form luminal
vesicles. Endosomes that contain multiple luminal vesicles are
called multivesicular bodies (MVBs). In many cells MVBs
fuse with lysosomes, or vacuoles in yeast, leading to the
destruction of exposed protein domains. However, in some
mammalian cells MVBs also serve more specialized functions.⁎ Corresponding author. Fax: +44 151 7945337.
E-mail address: C.Sanderson@liverpool.ac.uk (C.M. Sanderson).
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doi:10.1016/j.ygeno.2006.04.003In antigen-presenting cells MVBs form part of the major
histocompatibility complex II (MHCII) compartments (MIICs),
where MHCII is loaded with antigenic peptides [4]. In these
cells MVBs fuse with the plasma membrane thereby delivering
loaded MHCII molecules to the cell surface and releasing
vesicles called exosomes from the cell [5]; a variation of this
process is also observed in dendritic cells [6]. Interestingly, in
monocyte-derived macrophages HIV is known to utilize the
MVB/MIIC compartment as a site of particle assembly [7,8].
Also several of the proteins required for MVB formation are
also needed for budding of HIV particles at the plasma
membrane [9,10].
Much of our current understanding of MVB formation is
derived from pioneering genetic studies performed in yeast.
To date, more then 70 genes are known to be required for the
transport of proteins into vacuoles. These vacuolar protein-
sorting (VPS) genes have been grouped into six classes (A–F)
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mutants. The 18 class E VPS proteins are all required for
efficient degradation of surface receptor proteins and the
formation of MVBs [11,12]. Biochemical analysis of yeast
class E VPS mutants led to the proposal that class E proteins
are organized into three complexes called ESCRT I, II, and
III. In yeast the ESCRT I complex is thought to contain a
single copy of Vps23p and multiple copies of Vps28p and
Vps37p; in addition, Vps27p and Hse1p are also thought to
be associated with this complex [2,13,14]. The yeast ESCRT
II complex appears to be composed of three proteins: Vps22p,
Vps25p, and Vps36p [15]. In contrast four proteins (Vps20p,
Vps32, Vps24, and Vps2) appear to constitute the core of the
ESCRT III complex [16,17], with Did2p and Vps60p possibly
acting as peripheral auxiliary factors, which interact with the
Vps4p/Vta1 complex [14,18], which in turn facilitates
disassembly of the ESCRT III complex. A recent systematic
study of protein interactions occurring between 17 soluble
Class E proteins showed that these proteins are assembled
into a single interconnected network. In addition this study
demonstrated direct interaction between components of
ESCRT I and ESCRT III [14]. As such, it is not yet clear
if ESCRT complex assembly follows a conditional sequence
or whether ESCRT I and III can function independent of
ESCRT II.
Although many aspects of MVB formation appear to have
been conserved through evolution, the precise function of
individual mammalian ESCRT proteins and the basis for partner
specificity remain unclear. The situation in human cells is
further complicated by the fact that the human genome encodes
10 potential homologues of the six yeast ESCRT III proteins
[10,19]. These human proteins are referred to as CHMP1A
(GeneID: 5119; approved gene symbol PCOLN3), CHMP1B
(GeneID: 57132), CHMP2A (GeneID: 27243), CHMP2B
(GeneID: 25978), CHMP3 (GeneID: 51652; approved gene
symbol VPS24), CHMP4A (GeneID: 29082), CHMP4B
(GeneID: 128866), CHMP4C (GeneID: 92421), CHMP5
(GeneID: 51510), and CHMP6 (GeneID: 79643). What role
these additional mammalian components play in MVB
formation is largely undefined.
Interestingly, several of the human CHMP proteins have
both nuclear and cytoplasmic/vesicular distributions, and
CHMP1A has been shown to be required for both MVB
formation [19] and the regulation of cell cycle progression
[20]. As yet it is not clear if other components of the
human ESCRT III complex may also exhibit dual
functionality.
A combination of targeted yeast two-hybrid and GST pull-
down studies has been used to investigate interactions
occurring between predicted components of the human
ESCRT complexes [9,10]. While these data provide a good
insight into the potential organization of the human ESCRT
complexes, there are still areas of data paucity and ambiguity.
As yet, few interactions have been reported for the human
CHMP5 protein. In part this is due to the potential of CHMP5
to autoactivate reporter expression in some yeast two-hybrid
systems [9,10]. Although interactions between known com-ponents of the mammalian ESCRT III complex have been
studied in some detail, very few human CHMP proteins have
been used as “baits” to screen high-complexity yeast two-
hybrid libraries. As such, our knowledge of subunit
organization within the human ESCRT III complex and the
identity of key auxiliary factors for both cytoplasmic and
nuclear functions remain incomplete.
In this study we have performed a systematic yeast two-
hybrid analysis of all 10 human CHMP proteins. These
data provide a more comprehensive insight into the
complexity of the human CHMP protein interaction network
and the occurrence of conserved “interlog” interactions.
Finally data from 20 yeast two-hybrid library screens have
identified a range of novel interaction partners, which may
facilitate future characterization of novel pathway compo-
nents and the mechanisms of CHMP protein function and
regulation.
Results
Extended yeast two-hybrid analysis of human ESCRT III
component interactions
In contrast to previous yeast two-hybrid studies [9,10]
we observed no autoactivation on SD-minus Trp/Leu/Ade
plates with any of our (Ga14BD-X) CHMP bait constructs.
This discrepancy with previous studies is most likely due to
the high stringency of selection that is possible with the
yeast two-hybrid system used in our assays [21]. This lack
of autoactivation enabled us to perform comprehensive
yeast two-hybrid studies with all 10 human CHMP
proteins.
As the addition of large peptide domains is known to
have dramatic effects on CHMP protein function [10] we
thought it possible that some protein–protein interactions
may be blocked by the addition of large N-terminal GAL4
domain fusions. To test this possibility we utilized a range
of N- and C-terminal Gal4 bait and “prey” constructs (Fig.
1A) to generate a more comprehensive insight into ESCRT
III complex intersubunit interactions. The combined profile
of protein interactions detected in these studies is shown in
Figs. 1B–1D. In total we identified 25 subunit interactions
(Fig. 1E). Of these 15 were previously reported. However,
4 of the known interactions were previously detected only
by non-yeast two-hybrid methods. In addition, we observed
9 novel interactions, including several interactions involv-
ing CHMP5 and CHMP2B, which were underrepresented
in previous protein interaction studies. When C-terminal
prey domain fusions (Y-Gal4AD) were screened against N-
terminal bait constructs (Gal4BD-X) we observed signifi-
cant homodimerization of several ESCRT III components,
including Vps4A and CHMP 1A, 1B, 2A, 2B, 3, 4A, 4B,
and 5 proteins (Fig. 1C). Interestingly, CHMP4C and
CHMP6 showed no sign of homodimerization under any
of the conditions tested (Figs. 1B–1D), although homo-
dimerization of CHMP4C has been reported previously
[9].
Fig. 1. Extended analysis of component interactions within the human ESCRT III complex. (A) Vectors used to generate N- or C-terminal Gal4BD and Gal4AD yeast
two-hybrid constructs. (B–D) Results of targeted yeast two-hybrid assays using combinations of N- or C-terminal bait and prey fusions. (B) Interaction profiles
observed when bait and prey proteins were both expressed as N-terminal fusions (Gal4BD-X + GAL4AD-Y). (C) Interaction profiles observed when bait proteins were
expressed as N-terminal fusions while prey proteins were expressed as C-terminal fusions (Gal4BD-X + Y-GAL4AD). (D) Interaction profiles observed when bait
proteins were expressed as C-terminal fusions while prey proteins were expressed as N-terminal fusions (X-Gal4BD + GAL4AD-Y). Hatched, gray, and black boxes
shown in panels B–D represent weak, intermediate, or strong growth, respectively, on SD-minus Trp/Leu/Ade plates. Letter (A) shown in panel D indicates auto-
activation. (E) A graphical representation of all observed interactions. Circular arrows indicate homodimerization, dashed black arrows show interactions detected in
this study and in previous studies, solid black arrows indicate novel interactions detected in this study, and dotted arrows indicate interactions detected in this study that
were previously identified only by non-yeast two-hybrid methods.
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MIT domain containing protein VPS4A interacts with
multiple CHMP partners (1A, 1B, 2A, 4A, and 4B).
However, we observed no interaction between VPS4A and
CHMP 2B, 3, 4C, 5, or 6. Two previous yeast two-hybrid
studies also failed to detect clear interactions between VPS4
and CHMP2B or CHMP3; however, both of these interactions
were observed by GST pull-down methods [9]. Interestingly,
no interaction has yet been detected between Vps4 and
CHMP5.
As predicted several CHMP–CHMP interactions were
detected only with specific combinations of GAL4-fusion
constructs. This was particularly true for CHMP5, interactions
of which with other ESCRT III components could be observed
only when potential interaction partners were expressed in theN-terminal (Gal4AD-Y) prey format. In contrast CHMP5
homodimers were also observed when preys were expressed
in C-terminal (Y-Gal4AD) prey format, suggesting that
heterotypic interactions and homodimerization may have
different requirements.
To identify novel auxiliary factors, we used each of the 10
human CHMP proteins as baits to screen two high-complexity
human prey libraries derived from K562 cells and from fetal
brain. These screens revealed a large collection of novel
interaction partners (Fig. 2A and Table 1), all of which pass
high-stringency secondary yeast two-hybrid tests for both
reproducibility and partner specificity [22]. To ensure that
novel interactions involving CHMP proteins were not missed
due to sampling effects, which are inherent in library screening
methods, we also performed secondary targeted interaction
Fig. 2. Human CHMP protein interaction networks. (A) All binary interactions detected in this study. CHMP proteins are shown as larger black nodes, while nodes
corresponding to MIT domain-containing proteins are shown as hollow black rings. Novel interactions detected in this study are shown by black arrows, while known
interactions are shown by gray arrows. An interaction between spastin and CHMP1B, which was detected in our previous study, is represented by a dashed arrow. (B)
By extending the periphery of our human CHMP protein interaction network to include known interaction partners of each CHMP prey protein an additional loop of
SUMO-related proteins was detected. Novel interactions detected in this study are shown by black lines, while additional known interaction partners are joined by
dashed lines.
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library screen were systematically retested against all CHMP
proteins. Reassuringly ∼97% (29/30) of the interactions
detected in primary library screens were reconfirmed in these
reiterative matrix experiments. In addition, we detected a
further 30 interactions that were not detected in primary
screens. Interestingly prey clones that were isolated from
CHMP1B, CHMP2A, CHMP5, and CHMP6 screens demon-
strated strict fidelity for the original bait. In contrast some prey
clones isolated from CHMP3, CHMP4A, CHMP4B, and
CHMP4C screens showed broad, yet selective, interaction
profiles (Supplementary Fig. 1). Data from both library screens
and targeted matrix experiments were combined to investigate
the connectivity of our dataset. The resulting CHMP protein
interaction network (Fig. 2A) depicts many novel features,which may be useful in guiding future research into both the
nuclear and the cytoplasmic/endosomal functions of mamma-
lian CHMP proteins. For example; it is interesting to note that
we detected novel interactions between components of the
ESCRT III complex and several proteins that may form part of
signal transduction cascades. These include TRAF4AF1,
which interacts with CHMP1B, and CC2D1A, which was
found to interact with CHMP4A, 4B, and 4C. Also as
CHMP1A has been shown to have a role in cell cycle
progression and chromatin structure [20] it may be significant
to note that at least 19 of the 45 novel interactions detected in
this study involve proteins that have either known nuclear
functions or nuclear-related (GO) ontology annotations (Table
1). These include SSRP1 and SMARCA4, both of which are
thought to be involved in chromatin remodeling. In addition it
Table 1
Data from yeast two-hybrid library screens
Bait Bait gene ID Prey Prey gene ID K562 Fetal Brain Novel GO Interlog
CHMP1A 5119 UBE2I 7329 X X
VPS4A 27183 X Refs. [9,10] SC
CHMP1B 57132 TRAF4AF1 XM_031561 X X ST
SUCLG1 8802 X X
ASCC3L1 23020 X X X N
RAB11A 8766 X X X
AMSH 10617 X X
CNOT10 25904 X X N
SSRP1 6749 X X N/CH
RASSF7 8045 X X N/ST
CHMP2A 27243 NOL4 8715 X X N
EIF2B5 8893 X X N
LOC129531 129531 X X
CHMP2B 25978 PNMA1 9240 X X X N
PHGDH 26227 X X
LOC84661 84661 X X X N
C7orf30 115416 X X
CENTF 1063 X X CC
CHMP3 51652 AMSH 10617 X X Ref. [34] DM
TNPO3 23534 X X N
RAB11A 8766 X X
CHMP4B 128866 XM_351097 X X
CHMP4B 128866 X X Ref. [9] SC/DM
CHMP4A 29082 X X Ref. [9] SCDM
PIAS2 9063 X X N
EXOSC9 5393 X X
HIPK2 28996 X X N/ST
UBE2I 7329 X Ref. [23]
CHMP4A 29082 CC2D1A 54862 X X ST
TTC19 54902 X X
CDC2L5 8621 X X CC
SYT17 51760 X Ref. [23]
CHMP4C 92421 CC2D1A 54862 X X ST
TRPC4AP 26133 X X
CHMP5 51510 ZNF91 7644 X X N
RPL38 6169 X X
PDCD10 11235 X X
GTF3A 2971 X X N
ZNF142 7701 X X N
URG4 55665 X X
SWI/SMARCA4 6597 X X N/CH
LIP5 51534 X Refs. [14,35] SC
CHMP6 79643 EAP20 84314 X X Refs. [9,10,14] SC/DM
DREV1 51108 X X N
ELOF1 84337 X X N
AMSH 10617 GRB2 2885 X ND X ST
GRAP2 9402 X ND ST
STAM1 8027 X ND ST
STAM2 10254 X ND ST
CHMP3 51652 X ND X DM
CHMP1A 5119 X ND X
ALAS1 211 X ND X
AMN 81693 X ND X
UACA 55075 X ND X N
CTNNBL1 56259 X ND X N
MAP2K5 5607 X ND X ST
Protein interactions detected in 20 yeast two-hybrid library screens. Each human CHMP protein was used as a bait to screen both K562 and Fetal Brain yeast two-
hybrid prey libraries. The library from which each interaction was detected is indicated by a bold “X”. Known Interlog interactions are indicated by the species in
which the interaction was observed: SC, Saccharomyces cerevisiae; DM, Drosophila melanogaster. Gene Ontology (GO) terms extracted from GOA are shown for
interaction partners with potential nuclear (N) functions or proteins that may be involved in some aspect of signal transduction (ST), cell cycle progression (CC), or
chromatin remodeling (CH).
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recognized by multiple members of the CHMP family. These
highly connected preys include the SUMO conjugating
enzyme UBE2I, which was found to interact with CHMP1A,
CHMP4B, and CHMP5. Significantly an interaction between
CHMP4B and UBE2I was also detected in the recent large-
scale human interactome study performed by Rual et al. [23].
To investigate if preys at the periphery of our network could be
integrated into closed loops by the addition of further data we
searched the HIMAP, HPRD, and NCBI databases to identify
additional known interaction partners for each node in our
network. As a result of extending our network in this way we
were able to identify a new set of interconnected nodes, which
contain functionally related proteins. Of particular interest was
the formation of a network connecting CHMP1A, CHMP4B,
and CHMP5 with UBE2I, SUMO1, PIAS2, and HIPK2 (Fig.
2B), all of which are known to be involved in nuclear
sumolation processes.
In addition we also found that RAB11A and AMSH/
STAMBP both interacted with multiple CHMP proteins. (Fig.
2A and Supplementary Fig. 1). Although many of the
observed interactions may provide clues to the potential
nuclear and cytoplasmic functions of the different human
CHMP proteins we were particularly interested in two putative
interaction partners, both of which appeared to possess MIT-
like domains.
Additional MIT domain-containing proteins interact with
components of the human ESCRT III complex
Analysis of the domain composition of novel CHMP
interaction partners revealed two proteins, LOC129531 and
AMSH/STAMBP, that have sequence motifs that resemble the
MIT domains (IPR007330) of VPS4B [24] and spastin [25],
both of which bind to the human CHMP1B protein (Fig. 2A).
Although the uncharacterized LOC129531 protein is known to
contain an MIT domain, the human AMSH protein was not
known to be a member of the MIT domain family. However,
when the key MIT domain residues defined by Scott et al. [26]
were aligned with the N-terminal region of the human AMSH
protein (amino acids 34–113), we found that of the 38
consensus MIT domain residues, 4 were not conserved in
either AMSH or the human VPS4B protein. However, of the
remaining 34 residues, 22 (64%) were preserved in the human
AMSH protein and a further 4 had conserved amino acid
substitutions representing >76% conservation between the N-
terminal region of the human AMSH protein and residues in the
consensus MIT domain sequence (Fig. 3A). Furthermore,
analysis of the predicted helical nature of amino acids 34–113
of the human AMSH protein revealed three helical domains
(Fig. 3A), which resemble the pattern observed in known MIT
domain structures [26]. These data strongly suggest that AMSH
could be a new member of the human MIT domain family. As
the MIT domains of VPS4A and spastin are both known to be
required for interaction with CHMP proteins [25,27] we
performed a domain fragmentation study to determine which
domains of the human AMSH protein were required forinteraction with each of the human CHMP proteins. Domain
analysis of the human AMSH protein identified five domain
features, including MIT (IPR007330), MADS (IPR002100),
COIL, Mov34 (IPR000555), and CON (connexin-like) domains
(Fig. 3B). Therefore the AMSH protein was fragmented into
four fragments, which were designed to assess the requirement
for each domain in AMSH/CHMP protein interaction. Unfor-
tunately, fragment 1 (amino acids 1–104) exhibited mild
autoactivation in yeast two-hybrid assays (Figs. 3C and 3D).
However, fragment 2 (amino acids 1–248) interacted strongly
with CHMP1B, CHMP3, and CHMP4B. This fragment also
showed weak interactions with CHMP4A and CHMP1A. This
profile of selective interaction was very similar to that observed
for the full-length AMSH protein. Interestingly, neither
fragment 3 (amino acids 98–248) nor fragment 4 (amino
acids 98–424) was capable of binding to any of the human
CHMP proteins. Therefore, we predict that the N-terminal 100
amino acids are required for CHMP protein interaction.
Significantly this is also the region that encodes the putative
MIT domain.
Reciprocal yeast two-hybrid screening to identify novel
AMSH-interacting proteins
To investigate further the interaction profile of the human
AMSH protein we performed a reciprocal yeast two-hybrid
screen in which the AMSH protein was used as a bait to screen a
high-complexity human K562 prey library. This screen isolated
11 different prey proteins, each of which passed all of our
reproducibility and specificity tests [22]. The prey proteins
identified in this screen were GRB2 (GeneID: 2885), GRAP2
(GeneID: 9402), STAM 1 (GeneID: 8027), STAM2 (GeneID:
10254), UACA (Gene ID: 55075), CTNNBL1 (GeneID:
56259), CHMP3 (GeneID: 51652), ALAS1 (GeneID: 211),
MAP2K5 (GeneID: 5607), AMN (GeneID: 81693), and
CHMP1A (GeneID: 5119). Of these proteins GRAP2,
STAM1, and STAM2 are known AMSH interaction partners,
while GRB2, UACA, CTNNBL1, ALAS1, MAP2K5, AMN,
and CHMP1A represent novel interactions. A conserved
interlog interaction between CHMP3 and AMSH was also
observed in Drosophila melanogaster [28] and CHMP3 has
been shown to form an in vitro complex with AMSH and STAM
[34]. To investigate whether AMSH/CHMP1A, AMSH/
CHMP3, and LOC129531/CHMP2A interactions could be
observed in mammalian cells we then performed a range of
complementary protein interaction experiments in human cells.
Colocalization of interaction partners in HeLa cells
To establish if potential interaction partners colocalize when
coexpressed in mammalian cells, epitope-tagged versions of
CHMP1B, CHMP3, and AMSH or CHMP2A and LOC129513
proteins were transiently expressed in HeLa cells and the
relative distribution of partner proteins was analyzed by
confocal microscopy. Data presented in Fig. 4 show that a
partial yet distinct colocalization was observed between
CHMP1B and AMSH (Figs. 4A–4C), CHMP3 and AMSH
Fig. 3. The human AMSH protein contains an N-terminal MIT-like domain, which is required for CHMP protein interactions. (A) Alignment of the MIT domain of
human VPS4B and the corresponding N-terminal region (amino acids 34–113) of the human AMSH protein. Consensus MIT domain amino acid preferences are
shown above the aligned sequences; * indicates highly conserved residues; · indicates the highly conserved L64 residue, which is required for optimal interaction of
VPS4A and CHMP1B. Other conserved residues are shown as follows: h, hydrophobic residue; −, acidic residue; +, basic residue; l, Ile, Val, or Leu; u, Ala or Gly.
Boxes indicate where optimal MIT domain residues are conserved in the AMSH sequence. Dots below the aligned sequences show where neither the VPS4 nor the
AMSH sequence conforms to the ideal MIT domain consensus sequence. Shaded boxes above and below the aligned sequences show predicted helical domains. (B)
The human AMSH protein was divided into four fragments (F1–F4), which were designed to differentiate between predicted domains within the human AMSH
protein: MIT (IPR007330), MADS (IPR002100), COIL, Mov34 (IPR000555), and CON (connexin-like domain). Amino acid residues representing the start and end
of each fragment are indicated. (C and D) Each fragment was cloned into both bait and prey vectors before being used in targeted yeast two-hybrid assays against a
panel of complementary human CHMP proteins. Black and gray squares represent strong or weak growth, respectively, on SD-minus Trp/Leu/Ade plates. A
representative example of each matrix interaction assay is shown to the right in panels C and D.
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Fig. 4. Colocalization of putative partner proteins in HeLa cells. HeLa cells were transiently transfected with (A–C) EGFP-AMSH + myc-CHMP1B, (D–F) CHMP3-
EGFP + myc-AMSH, or (G–I) EGFP-LOC129531 + myc-CHMP2A. In each case cells were fixed 24 h after transfection before being stained with a monoclonal anti-
cmyc antibody followed by a Cy3-conjugated anti-mouse antibody (B, E, and H).
340 H.T.H. Tsang et al. / Genomics 88 (2006) 333–346(Figs. 4D–4F), and CHMP2A and the LOC120513 protein
(Figs. 4G–4I). In each case proteins were seen to be colocalized
on punctate vesicular structures.
Having established that both AMSH and LOC120531
colocalize with their putative CHMP binding partners, we
then performed protein complementation assays to demonstrate
that each of these putative interactions can take place in live
human cells. For this purpose we employed the split β-
lactamase system [29,30]. This approach has previously been
used to study a range of protein interactions in live human cells,
including an interaction between CHMP1B and the MIT
domain-containing protein spastin [25]. To assess the degree
and specificity of each putative interaction cells were
cotransfected with either a combination of predicted interaction
partners (CHMP1B/AMSH, CHMP3/AMSH, or CHMP2A/
LOC129531) or combinations of inappropriate interaction
partners (ATP6G/CHMP1B, ATP6G/CHMP3, ATP6G/
CHMP2A, ATP6E/LOC129531, or ATP6E/AMSH). In addi-
tion cells were also transfected with two known interaction
partners (ATP6G and ATP6E) or vectors containing only the
two complementary β-lactamase fragments. Results from these
experiments show that when each of our predicted interaction
pairs, CHMP1B/AMSH, CHMP3/AMSH, and CHMP2A/
LOC219531, was coexpressed we detected significantly more
cells expressing reconstituted β-lactamase activity than wasobserved when either interaction partner was coexpressed with
an inappropriate interaction partner (Figs. 5A–5C). Moreover
interaction levels observed between predicted interaction pairs
were always far greater than background levels observed when
complementary β-lactamase fragments were expressed alone
(Figs. 5B–5D). Finally, although the absolute number of β-
lactamase-positive cells varied between independent experi-
ments the relative proportion of positive cells observed for true
interaction partners compared to that observed for negative
control or inappropriate pairings was comparable directly
between independent experiments (Fig. 5D).
Coprecipitation of CHMP2A/LOC129531, CHMP1B/AMSH,
and CHMP3/AMSH complexes from transiently transfected
cells
To substantiate further our colocalization and split β-
lactamase data, we performed coprecipitation experiments to
demonstrate that each of the three CHMP proteins (1B, 2A, and
3) could be immunopurified with its respective binding partner
following transient coexpression in mammalian cells. This was
achieved by coexpressing one partner as an EGFP fusion and
the other partner as a cmyc fusion (Fig. 6). Following cell lysis
EGFP fusion proteins were precipitated using an anti-EGFP
polyclonal antiserum and the degree of association between
Fig. 5. Analysis of partner interactions in live human cells. Putative interaction partners were fused to complementary fragments (BLF1 or BLF2) of the β-lactamase
enzyme. In this assay either expression of full-length β-lactamase (FLβ-LAC) or reconstitution of β-lactamase activity due to partner interactions induces the
conversion of the CCF2-AM reporter from green to blue. (A) A representative example of a β-lactamase PCA assay in which HEK293 cells were transiently
transfected with FLβ-LAC (A), predicted interaction partners CHMP3-BLF1 + AMSH-BLF2 (B) or CHMP1B-BLF1 + AMSH-BLF2 (C), or combinations of
inappropriate interaction partners CHMP3-BLF1 + ATP6G-BLF2 (D), CHMP1B-BLF1 + ATP6G-BLF2 (E), or ATP6E-BLF1 + AMSH-BLF2 (F). (B and C) The
proportion of β-lactamase-positive cells observed when appropriate or inappropriate combinations of BLF fusion proteins were coexpressed. (D) The relative
proportions of β-lactamase-positive cells observed for test or control combinations of protein partners were consistent between independent experiments.
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Western blotting using a monoclonal anti-cmyc antibody. In
each case control coprecipitations were also performed in which
cmyc-tagged proteins were coexpressed with EGFP alone. Data
presented in Fig. 6 show that cmyc-tagged proteins were
coprecipitated only when expressed with the predicted
interaction partner fused to EGFP and not when coexpressedwith EGFP alone. Collectively data from these three different
interaction studies provide strong evidence that the predicted
interactions between CHMP1B/AMSH, CHMP3/AMSH, and
CHMP2A/LOC129531 may well be physiologically relevant.
As such these data demonstrate that two further MIT domain-
containing proteins are recruited to the ESCRT III complex in
mammalian cells.
Fig. 6. Coprecipitation of transiently expressed interaction partners. HECT293 cells were transiently transfected with the following combinations of protein expression
vectors: (A) AMSH-EGFP + myc-CHMP1B or myc-CHMP1B + EGFP, (B) CHMP3-EGFP + myc-AMSH or myc-AMSH + EGFP, or (C) CHMP2A-EGFP + myc-
LOC129531 or myc-LOC129531 + EGFP. In each case cells were prepared for immunoprecipitation 24 h after transfection. EGFP-tagged proteins were precipitated
from soluble extracts using a polyclonal anti-EGFP antibody (+) before being processed for Western blotting. The presence of associated myc-tagged proteins was then
analyzed by Western blotting with a monoclonal anti-cmyc antibody. In each case mock precipitations were performed in the absence of the anti-EGFP antibody (−).
For each precipitation reaction the expression levels of input proteins were analyzed to ensure comparable starting expression levels (Input).
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late or distended hybrid endosomes we compared the
distribution of individual interaction partners with that of
the M6PR protein, which is known to localize to late
endosomes. In each case we observed a partial colocalization
of CHMP1B, CHMP3, AMSH, and LOC129531 with
M6PR-positive membranes, implying that the observed
interactions between CHMP proteins and MIT domain-
containing proteins may in part occur on late endosomal
membranes (Fig. 7).
Discussion
Although the basic principles of MVB formation appear to
be conserved through evolution, there has been a significant
expansion in proteome complexity between yeast and mam-
mals. In addition, mammalian cells have evolved specialized
adaptations of MVB function [4–6]. As such, extrapolation of
data from model organisms may provide an incomplete view of
the molecular mechanism of MVB formation in mammalian
cells. For example, the occurrence of three forms of CHMP4
(Vps32p/Snf7p), two forms of CHMP2 (Vps2p), and two forms
of CHMP 1 (Did2p) in mammalian cells raises the issue of how
these additional components assemble to form the human
ESCRT III complex. As yet, it is not clear if all 10 mammalianESCRT III components assemble into a distinct structure with
invariant composition or stoichiometry.
Data from our yeast two-hybrid studies support and extend
previous studies [9,10], which show that direct interactions can
occur between the different CHMP protein isoforms, including
CHMP1A and CHMP1B and different combinations of the
CHMP4 proteins. Therefore, it is possible that rather than being
mutually exclusive, the extra forms of each CHMP protein may
associate within the same complex. This possibility is supported
by the fact that transiently expressed forms of CHMP1A and
CHMP1B and combinations of the different CHMP4 proteins
colocalize to common subcellular structures in mammalian cells
(Supplementary Fig. 2). Given the diversity of mammalian cell
types it was also possible that CHMP isoforms may be
expressed in different cell types. However, analysis of the
expression patterns of all 10 human CHMP transcripts in a
range of human cells and tissues shows that both forms of
CHMP1 and CHMP2 are coexpressed in the same cell. Equally,
multiple forms of CHMP4 are frequently expressed in the same
cell or tissue, although CHMP4C is frequently expressed at a
very low level compared to the other two isoforms (Supple-
mentary Fig. 3). Therefore at present it would appear that
different CHMP isoforms may exist in the same ESCRT
complex. However, we cannot yet rule out the possibility that
multiple ESCRT complexes with different core components
Fig. 7. CHMP proteins and their novel MIT domain-containing partners show partial colocalization with the late endosomal marker M6PR. HeLa cells were transiently
transfected with (A–C) CHMP1B-EGFP, (D–F) CHMP2A-EGFP, (G–I) CHMP3-EGFP, (J–L) LOC129531-EGFP, or (M–O) EGFP-AMSH. At 24 h posttransfection
cells were fixed and counterstained with a rabbit anti-M6PR polyclonal antiserum followed by a secondary Cy3 anti-rabbit antiserum (B, E, H, K, N). The degree of
colocalization is shown in panels C, F, I, L, and O.
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cell. Clearly this type of combinatorial system could increase
the fidelity and range of protein sorting of recycling events.
Our data also show that several of the human CHMP proteins
can form homodimers, in addition to interacting with other
CHMP proteins and a range of noncore auxiliary factors. Assuch, it is not yet clear what determines partner preferences in
vivo. It is possible that CHMP–CHMP partner preference may
be determined by differential binding affinities as observed for
the organization of structurally related proteins within the
human LSM ring complexes [31]. Equally, homodimerization
could also prevent heterotypic CHMP–CHMP interactions,
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ation as proposed for the VPS4 proteins [27]. Alternatively,
homo- and heterotypic interactions may utilize different
interaction surfaces. Given the similarity of the different
CHMP proteins the latter possibility may seem less probable;
however, the observation that CHMP5 homodimers were
observed when both N- and C-terminal yeast two-hybrid
GAL4BD fusions were used, whereas interaction between
CHMP5 and other CHMPs could be detected only when N-
terminal GAL4BD constructs were used, implies that at least for
CHMP5 this possibility cannot yet be totally discounted.
Unlike all other CHMP proteins no interaction has yet been
observed between CHMP5 and VPS4AP; however, CHMP5
does interact with Vta1. The proposed structure of the VPS4AP/
VTA1 complex depicts two stacked rings of six VPS4A
proteins, each with a peripheral band of six VTA1 proteins [27].
It is therefore possible that the role of CHMP5 is to tether or in
some way regulate the assembly or function of the VPS4/VTA1
complex, whereas other CHMP proteins may interact only with
the VPS4 protein core as they are extruded from the membrane.
As some CHMP proteins have both a nuclear and a
cytoplasmic distribution it is feasible that different partner
preferences may be exhibited in different subcellular compart-
ments. Interestingly a significant number of prey proteins
identified in our yeast two-hybrid screens have known or
predicted nuclear functions. In particular we identified a group
of interaction partners including HIPK2, PIAS2, and UBE2I
(Fig. 2B), all of which are known to be involved in the
sumolation of nuclear proteins. In this respect it is intriguing to
note that Stauffer et al. [20] have shown that nuclear forms of
CHMP1A are in some way posttranslationally modified. As
several of the human CHMP proteins do have consensus
sumolation sequences it is possible that UBE2I may play a role
in regulating the function of CHMP proteins within the nucleus
of human cells.
One of the primary aims of this study was to use a
systematic yeast two-hybrid approach to identify novel
binding partners, which may provide new insights into the
process of MVB formation in mammalian cells. Interestingly,
studies in yeast suggest that the ubiquitin-conjugating enzyme
UBC13 is in some way required for the internalization of
surface receptors. By extrapolation this in turn implicates a
role for K63-linked ubiquitin chains in receptor internalization
and degradation. Recent studies provide direct evidence that
this prediction is correct in human cells [36]. However, how
components of the human ESCRT III complex engage or
disengage K63-linked proteins remains unclear. The ability of
multiple ESCRT III proteins to recruit the AMSH protein,
which is known to be an endosome-associated ubiquitin
isopeptidase with the ability to cleave K63-linked ubiquitin
chains [32], implies that the presence or absence of K63
chains may affect the ultimate fate of some internalized
surface receptor proteins. In this respect it is interesting to
note that UBC13 and AMSH were both identified as
suppressors of the Ste12Δ phenotype, which results from
defects in vesicular transport and the formation of distended
vacuoles [33].Although the AMSH/CHMP3 interaction is conserved
between Drosophila and mammals, our data show that in
human cells AMSH binds to a distinct subset of ESCRT III
components, with robust interactions also occurring between
CHMP1A and CHMP1B and CHMP4A (Fig. 3). The
recruitment of two further MIT domain-containing proteins to
the human ESCRT III complex raises several interesting issues.
To date five MIT domain-containing proteins have been found
to interact with components of the human ESCRT III complex
(Fig. 2A). However, as several MIT domain proteins exhibit an
ability to bind to the same CHMP protein it will be important to
determine if the binding of different endogenous MIT domain-
containing proteins is antagonistic or if multiple MIT domain-
containing proteins can be recruited to the same ESCRT
complex. Also, as each MIT domain protein appears to interact
with only a subset of CHMP proteins, a more detailed dissection
of these interactions is required to explain the specificity of MIT
domain–CHMP interactions. At present it would appear that the
ESCRT III complex may facilitate the recruitment of a diverse
set of functionally distinct MIT domain-containing proteins,
some of which may have antagonistic functions.
Although there are still many aspects of MVB formation
and CHMP protein function that remain unanswered, data
presented in this report provide a more comprehensive
insight into the spectrum of potential CHMP protein
interactions. As such these data will provide potentially
important leads to characterizing new pathway components,
defining interaction specificities, and guiding future research
into multiple aspects of the precise function of different
human CHMP proteins.Materials and methods
Construction of yeast two-hybrid bait and prey clones
Complete open reading frames of the 10 human CHMP proteins were
amplified by PCR using the proofreading enzyme Platinum Pfx polymerase
(Invitrogen). The GenBank/RefSeq accession numbers and IMAGE IDs for each
clone are as follows: CHMP1A, AF281063:3507057; CHMP1B, AF281064:
3928338; CHMP2A, AF042384:3051024; CHMP2B, AF151842:3460712;
CHMP3, AF219226:3660116; CHMP4A, AF161483:4295071; CHMP4B,
NM_176812:5173394; CHMP4C, NM_152284:3828410; CHMP5,
AF132968:4044464; CHMP6, NM_024591:3604039. With respect to the
nomenclature of human CHMP proteins, it is important to note that the
nomenclature used in this article for human CHMP4A and CHMP4B is in
accordance with the current annotation of the human genome, which is the
reverse of that used in previous publications [9,10], in which CHMP4A was
assigned the accession number NM_176812:5173394 and CHMP4BAF161483:
4295071. In each case primers were designed from the reference mRNA
sequence and were tagged at the 5′ end with GATEWAY recombination
cloning sequences. PCR products were then cloned by the gap-repair
recombination method into the GATEWAY-compatible bait vector pGBAD-B
or pB-GBD and the equivalent prey vector pACTBD-B or pB-ACT2. All bait
constructs were assembled in the PJ69-4A MATa strain, while prey constructs
were assembled in the complementary mating type switched strain PJ69-4A
MATα. Targeted matrix experiments were performed as described previously
[31].
Yeast two-hybrid library screens
Library screens were performed as described previously [22].
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HeLa cells were seeded onto sterile glass coverslips in six-well plates at an
approximate density of 0.5 × 105 cells/well. After an overnight incubation cells
were transfected with 400 ng of vector DNA in combination with Effectene
transfection reagent (Qiagen), in accordance with the manufacturer's
instructions. Transfected cells were incubated for either 24 or 48 h in
DMEM (Life Technologies) containing 10% fetal bovine serum (Sigma),
100 U/ml penicillin and 100 mg/ml streptomycin (Sigma), and 2 mM L-
glutamine (Sigma). Cells were then washed in PBS (Sigma) prior to being
fixed at room temperature for 15 min in 4% formaldehyde/PBS. Fixed cells
were then washed in PBS before being permeabilized in PBS/0.1% Triton X-
100 (Sigma) for 5–10 min at room temperature. Following permeabilization
cells were washed three times in PBS before being incubated in blocking
solution (PBS, 10% FBS). Where appropriate cells were stained using a
primary mouse monoclonal anti-cmyc antibody followed by a rabbit
polyclonal anti-M6PR. After being washed three times in blocking buffer
cells were incubated with a Cy3-conjugated anti-mouse or anti-rabbit
secondary antibody (Jencons) as appropriate. In each case secondary antisera
were used at a dilution of 1/300 in blocking buffer. Following staining
coverslips were sequentially washed in PBS and distilled H2O before being
mounted in Vectorshield (Vector Laboratories, Inc.).
Coimmunoprecipitation experiments
Approximately 1 × 105 HEK293T cells were cotransfected with the desired
combination of EGFP and cmyc-tagged fusion proteins. To control for
interaction specificity each myc-tagged protein was also independently
cotransfected with a comparable plasmid expressing only EGFP. At 24 h
postinfection cells were washed twice with PBS before being lysed in 600 μl of
ice-cold lysis buffer containing 1% (v/v) NP-40, 150 mM NaCl, 10 mM Tris–
HCl (pH 7.5), 0.02% sodium azide, 1 mg/ml BSA, and 0.5% protease inhibitor
cocktail. A 100-μl aliquot of the total lysate was removed to assess relative
expression levels and the remaining lysate was centrifuged at 13,000g for
15 min at 4°C. The resulting soluble fraction was then removed and extracts
were incubated overnight at 4°C with rabbit polyclonal anti-GFP primary
antibody (Abcam) at a concentration of 1:250. Protein A–Sepharose beads
(50 μl of a 50% slurry per reaction) were then added and samples were incubated
at 4°C for a further 2 h. Beads were then isolated by brief centrifugation before
being washed three times in NP-40 buffer containing BSA and then in NP-40
buffer without BSA. Beads were then resuspended in 5× SDS–PAGE sample
buffer and heated for 5 min at 95°C. Bound proteins were then resolved by
standard SDS–PAGE before being transferred to membranes for Western blot
analysis. Blots were stained using mouse monoclonal anti-myc clone 4A6
primary antibody (Upstate) at a concentration of 1:250.
Split β-lactamase protein complementation assays
GATEWAY compatible split-component β-lactamase expression vectors
were constructed as described previously (HMG 1). HEK293T cells were split
24 h prior to transfection and seeded at a density of 2.5 × 105 cells per well in
two-well glass chamber slides (Nunc Lab-Tech II Chamber Slide System) in
DMEM/10% FBS, 1% penicillin and streptomycin. In each case cells were
transfected with ∼300 ng of plasmid DNA using Effectene (Qiagen) according
to the manufacturer's instructions. At 48 h posttransfection cells were washed
once and resuspended in 750 μl of Hanks' balanced salt solution (Life
Technologies). The relative level of reconstituted β-lactamase activity was then
assessed using the GeneBLAzer detection kit (Invitrogen) according to the
manufacturer's instructions. Following addition of the cells permeable substrate
CCF2/AM cells were incubated for 1 h in the dark before being analyzed by
fluorescence microscopy using an Olympus IX81 inverted epifluorescence
microscope fitted with a 40× objective. Simultaneous acquisition of two-color
fluorescence was performed in real time using a 400DF15 excitation filter and
dual-view imaging system (Optical Insights) containing a filter cube with both
450DF65 and 535DF35 emission filters (OMEGA Optical). Cell R imaging
software (Olympus) was used for the analysis of multicolor images. The relative
proportion of cells expressing reconstituted β-lactamase activity was assessedby counting the number of blue (positive) and green (negative) cells in 10
random fields of view from each slide.
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